- How to ensure your study is prioritised in a competitive industry
- Aligning CRO, site and sponsor priorities so everyone is supported in working towards the same goal
- Successfully partnering a CRO team with your internal departments to allow for effective communication across all stages of the trial
- CRO monitoring and oversight: How to make processes efficient and effective
Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData
Early-phase oncology development is evolving rapidly, with a growing need for smarter trial designs, faster regulatory pathways, and deeper collaboration with sites. This session explores how AI-driven protocol design, streamlined fast-track approvals, and strategic site partnerships can transform study execution from design to delivery. Through practical insights and real-world examples, we will discuss how technology and collaboration with regulators and sites can help bring therapies to patients faster.
As with all therapeutic areas, artificial intelligence is generating significant buzz in oncology research. But where does it offer meaningful impact today, and where is there still work to be done? In this session, we’ll explore
- The practical realities of applying AI tools within the context of electronic clinical outcomes assessment (eCOA) in oncology trials where complex symptom profiles, high patient burden, and global trial scale demand more intelligent solutions.
- Discuss meaningful targets for AI use today, to generate operational efficiencies in study setup and translation
- Explore the future promise of adaptive, patient-facing tools that can better capture quality-of-life data and treatment response
- This session offers an honest look at what’s achievable now, what’s emerging, and how sponsors and CROs can think strategically about this fast-moving future in oncology.
